The demand for estrogen patches has risen dramatically, with an increase of 26% following the U.S. Food and Drug Administration’s (FDA) decision in November 2025 to remove a longstanding black box warning associated with hormone replacement therapy. This reversal, aimed at addressing concerns over dementia, cardiovascular diseases, and breast cancer, has resulted in a significant surge in requests for estrogen patches, a common form of hormone therapy used by women experiencing menopause.
:max_bytes(150000):strip_icc():format(jpeg)/estrogen-patch-hip-4926-33111e8d74fa477cae9465341950a136.jpg)
The FDA’s Commissioner, Dr. Marty Makary, commented on the situation, stating that the previous risks had been exaggerated, creating a “fear machine” that continues to persist. The removal of this warning marks a pivotal change in the landscape of hormone therapy, allowing for greater acceptance and utilisation of these treatments. However, the increase in demand has led to notable challenges, as pharmacies struggle to keep up amid issues in the supply chain and production capacities.
CVS Health, the largest pharmacy chain in the U.S., confirmed these supply issues, indicating that manufacturers have struggled to provide enough hormone replacement therapies (HRT) in recent weeks. A spokesperson emphasised that they are working closely with patients and healthcare professionals to explore available alternatives whenever possible.
In light of the rising demand, customers reliant on estrogen patches are finding it increasingly difficult to access their medications. Many women have voiced their struggles, with reports of inconsistent dosing becoming a concerning trend. Nicole Stark, a patient who uses the patches, shared her recent experience with PBS, explaining how the absence of the medication had led to overwhelming symptoms. “The night sweats have been intense. My irritability is definitely not in check… it’s really unsettling,” she revealed.
Trevia Mantz, another user, described her situation as one of panic, having missed doses of her medication. After navigating the complexities of insurance authorisations to switch manufacturers, she was ultimately able to obtain her patches. Such stories highlight the dire consequences of the shortage; for many women, the patches are crucial for relieving distressing menopausal symptoms.
Amneal Pharmaceuticals, which produces generic alternatives to branded hormones, acknowledged the alteration in the medication’s landscape following the FDA’s announcement. The company reported a significant uptick in the interest for estradiol transdermal patches and asserted that while some patients may face challenges in accessing products, they are committed to fulfilling their supply requirements and are actively working to enhance production.
Similarly, Viatris, another manufacturer of estrogen patches, expressed its dedication to ensuring availability for women seeking these vital treatments. The company is focused on expanding its production capacity to meet the surging demand while maintaining its commitment to safety and efficacy in women’s health products.
Experts have indicated that the shortage may persist for as long as three years, which raises concerns about the accessibility of this essential therapy for many women. Nonetheless, Dr. Lauren Streicher, an obstetrics and gynaecology professor at Northwestern University’s Feinberg School of Medicine, reassures patients that there are alternative transdermal options available. She explains that although patches are popular due to their skin absorption, which avoids certain risks associated with oral administration, therapies such as creams, sprays, and gels are equally effective and safe.
As demand for estrogen patches continues to surge, both consumers and healthcare providers are faced with navigating the complexities of a fluctuating supply. The ongoing situation underscores the importance of maintaining open lines of communication between manufacturers, pharmacies, and patients to ensure that those in need can receive the appropriate care and treatment.
While the initial decision to lift the black box warning has opened pathways for women seeking hormone therapy, the accompanying supply crisis raises urgent questions about how to best support patients in managing their menopausal symptoms. The healthcare community will need to work collaboratively to explore viable options to address these heightened needs, ensuring that women have access to the therapies they require during this pivotal stage of life.